Novartis says cancer drug Glivec had 94 pct US market share in July-August 2007 |
|
|
|
Published
:
Wed, 12 Sep 2007 17:46
|
ZURICH (Thomson Financial) - Novartis AG's blockbuster cancer drug Glivec had a 94 pct market share in the US during the months of July and August 2007, said the head of Novartis' oncology division David Epstein at the Pharma Brand and Business Review in East Hanover, New Jersey.In 2006, Glivec had sales of 2.6 bln usd and Novartis forecasts combined full-year peak sales of Glivec and cancer drug Tasigna at 4 bln usd.Novartis expects marketing approval for Tasigna from regulatory authorities in the US and Europe in the fourth quarter, and in the second half of 2008 in Japan.Oncology drug Femara should develop into another blockbuster from 2008, said Epstein, adding that it is one of Novartis' ten fastest-growing products.In other developments, Epstein said that blockbuster bone loss treatment Zometa has a market share of 75 pct, and he expects sales growth to accelerate from the second half of 2008 in spite of competition from Ibandronate, Clodronate and Pamidronate.sarah.fenwick@thomson.comsf/mas/ajbCOPYRIGHTCopyright AFX News Limited 2007. All rights reserved.The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.
|
|
|
|
|
|
|
| Stock
Quotes * |
|
NASDAQ
|
|
2792.28 |
22.57 (
0.81 %)
|
| SYMBOL (
2012-01-19 ) |
| LAST |
CHANGE
|
|
CARNIVAL
(
11:35am )
|
|
2017.00 |
46.00 (
2.42 %)
|
|
WHITBREAD
(
11:35am )
|
|
1662.99 |
33.99 (
2.09 %)
|
| SYMBOL (
2012-01-19 )
|
| LAST |
CHANGE
|
|
IBM
(
12:34pm ) |
|
181.50 |
0.43 (
0.24 %)
|
| SYMBOL (
2012-01-19 )
|
| LAST |
CHANGE
|
|
|
Print this Story
Novartis loses case in India over patent for anti-cancer drug Glivec 